WallStSmart

Accelerate Diagnostics Inc (AXDX)vsDexCom Inc (DXCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 41086% more annual revenue ($4.82B vs $11.70M). DXCM leads profitability with a 19.3% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 72/100 (B).

AXDX

Avoid

25

out of 100

Grade: F

Growth: 2.7Profit: 3.0Value: 5.0Quality: 5.0

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.7Profit: 8.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.67
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AXDX.

DXCMUndervalued (+89.6%)

Margin of Safety

+89.6%

Fair Value

$656.95

Current Price

$75.14

$581.81 discount

UndervaluedFair: $656.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXDX0 strengths · Avg: 0/10

No standout strengths identified

DXCM4 strengths · Avg: 9.0/10
Return on EquityProfitability
31.5%10/10

Every $100 of equity generates 31 in profit

EPS GrowthGrowth
92.2%10/10

Earnings expanding 92.2% YoY

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

Areas to Watch

AXDX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$859,9203/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.8x4/10

Trading at 9.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : AXDX

AXDX has a balanced fundamental profile.

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.

Bear Case : AXDX

The primary concerns for AXDX are EPS Growth, Market Cap, Return on Equity.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Key Dynamics to Monitor

AXDX profiles as a value stock while DXCM is a mature play — different risk/reward profiles.

DXCM carries more volatility with a beta of 1.45 — expect wider price swings.

DXCM is growing revenue faster at 15.0% — sustainability is the question.

DXCM generates stronger free cash flow (449M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (72/100 vs 25/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accelerate Diagnostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Accelerate Diagnostics, Inc., an in vitro diagnostic company, offers solutions for diagnosing serious infections in the United States, Europe, and the Middle East. The company is headquartered in Tucson, Arizona.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Want to dig deeper into these stocks?